The Management of Dyslipidaemia in Patients with Type 2 Diabetes Mellitus Receiving Lipid-Lowering Drugs: A Sub-Analysis of the CEPHEUS Findings

Abstract

The results of this study highlight the suboptimal management of dyslipidaemia in T2DM patients at high and very high risk of CVD.

Current gaps in management and timely referral of cardiorenal complications among people with type 2 diabetes mellitus in the Middle East and African countries: Expert recommendations

“…Globally, the MENA and AFR region had the highest (18.1%) prevalence of T2DM in 2021 (Figure 1). 14 The majority (90%) of people with T2DM in MENA and AFR are overweight or obese, with poor control of low‐density lipoprotein cholesterol levels, resulting in increased CV risk 15,16 . T2DM is a major risk factor for the development of cardiorenal complications—58% of individuals with T2DM develop chronic kidney disease (CKD), which concurrently increases the risk of heart failure (HF) and MI 17 .…”

“…The combination of HF and CKD is associated with the highest CV risk (HR 3.91; 95% CI, 3.02‐5.07) and all‐cause mortality risk (HR 3.14; 95% CI, 2.90‐3.40) 28 . Table S1 provides an overview of the cardiorenal burden and associated risk factors in MENA and AFR 9,15,16,20‐23,26,27,29‐36 . Reliable and consistent approaches are needed to measure routine cardiorenal parameters to guide clinical decision‐making in T2DM.…”

“…14 The majority (90%) of people with T2DM in MENA and AFR are overweight or obese, with poor control of low‐density lipoprotein cholesterol levels, resulting in increased CV risk. 15 , 16 T2DM is a major risk factor for the development of cardiorenal complications—58% of individuals with T2DM develop chronic kidney disease (CKD), which concurrently increases the risk of heart failure (HF) and MI. 17 The multicountry DISCOVER study among patients initiating a second‐line glucose‐lowering therapy reported that only 1 in 10 individuals in MENA and AFR had glycosylated hemoglobin (HbA1c) < 7.0%, alongside a high burden of cardiometabolic risk factors including hypertension and dyslipidemia.…”

“… 28 Table S1 provides an overview of the cardiorenal burden and associated risk factors in MENA and AFR. 9 , 15 , 16 , 20 , 21 , 22 , 23 , 26 , 27 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 Reliable and consistent approaches are needed to measure routine cardiorenal parameters to guide clinical decision‐making in T2DM. Alongside the substantial burden, cardiorenal diseases incur the highest short‐ and long‐term health care costs in T2DM and are important parameters associated with increased health care resource utilization.…”